Ironwood Pharmaceuticals, Inc. Stock Analysis & AI Score

Ironwood Pharmaceuticals, Inc. (IRWD) has an ST Score of 66.4 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate IRWD a Hold, with a price target of $6.68 (+59.4% vs the current price). Our ST Score grades it B (66.4/100). The ST Score is a data-driven signal, not a recommendation.

Valuation C-, Profitability A-, Financial Strength B+, Momentum A, Growth C, Forecast B+.

Ironwood Pharmaceuticals, Inc. (IRWD) earns a valuation grade of C-, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Ironwood Pharmaceuticals, Inc. (IRWD) earns a growth grade of C, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Ironwood Pharmaceuticals, Inc. (IRWD) earns a profitability grade of A-, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Ironwood Pharmaceuticals, Inc. (IRWD) earns a financial strength grade of B+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Ironwood Pharmaceuticals, Inc. (IRWD) is $6.68 from 30 analysts, which is +59.4% versus the recent price of $4.19.

Ironwood Pharmaceuticals, Inc. (IRWD) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.